Patients urged to carry extra batteries as Medtronic recall affects 24,595 insulin pumps that may stop delivering insulin ...

The FTC sued pharmacy benefit managers over their roles in increasing insulin prices over the past decade. The News talked to ...

High blood sugar levels can put you at risk of type 2 diabetes, heart problems and kidney failure and is mainly caused by not exercising and having a poor diet.

The cap applies to those who have Part D prescription drug coverage, whether through a stand-alone plan or as part of a ...

A new treatment combining ReCET and semaglutide could eliminate the need for insulin in type 2 diabetes, with 86% of ...

Both have campaigned for lower prescription costs. Kamala Harris has promised to expand President Biden’s policies. Donald ...

which are negotiated with drug manufacturers and are tied to a drug’s list price. Insulin products with higher list prices result in higher rebates and fees for the PBMs, the complaint alleges.

The companies — CVS-owned Caremark Rx, Cigna Group's Express Scripts and UnitedHealth Group's Optum Rx — acted in ways that stifled industry competition for insulin drugs, including by using ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more. By Reed Abelson and ...

This new insulin might mean fewer injections and better blood sugar control — both up and down — for diabetes patients.

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

Results from a new study suggest a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could ...